Salarius Pharmaceuticals Stock Scheduled to Reverse Split on Monday, June 17th (NASDAQ:SLRX)

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) are going to reverse split on the morning of Monday, June 17th. The 1-8 reverse split was announced on Monday, June 17th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th.

Salarius Pharmaceuticals Trading Up 1.9 %

NASDAQ:SLRX opened at $0.45 on Thursday. The company has a market capitalization of $2.14 million, a P/E ratio of -0.17 and a beta of 1.03. The firm has a 50-day moving average price of $0.48 and a two-hundred day moving average price of $0.56. Salarius Pharmaceuticals has a twelve month low of $0.40 and a twelve month high of $1.81.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($6.70) by $6.29. On average, equities research analysts predict that Salarius Pharmaceuticals will post -26.8 earnings per share for the current year.

Institutional Trading of Salarius Pharmaceuticals

A hedge fund recently raised its stake in Salarius Pharmaceuticals stock. Armistice Capital LLC increased its position in shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) by 105.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 225,000 shares of the company’s stock after acquiring an additional 115,364 shares during the quarter. Armistice Capital LLC owned approximately 5.71% of Salarius Pharmaceuticals worth $148,000 as of its most recent filing with the SEC. 11.88% of the stock is currently owned by institutional investors.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.